Spero Therapeutics (SPRO) Share-based Compensation (2016 - 2026)

Spero Therapeutics has reported Share-based Compensation for 11 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 28.41% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (down 47.0% YoY), and the FY2025 full-year result was $4.3 million, down 44.5% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.1 million, up from $1.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $3.2 million in Q1 2022, with the low at $714000.0 in Q2 2025.
• Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $1.9 million in 2023.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 59.43% — and 2025, when it tumbled 66.21%.
• Spero Therapeutics' Share-based Compensation stood at $2.5 million in 2022, then slipped by 20.02% to $2.0 million in 2023, then dropped by 24.74% to $1.5 million in 2024, then tumbled by 33.0% to $1.0 million in 2025, then advanced by 10.63% to $1.1 million in 2026.
• The last three Share-based Compensation figures came in at $1.1 million (Q1 2026), $1.0 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.